CONTINEUM THERAPEUTICS INC CLASS A (CTNM)
Health Care · biotechnology · NASDAQ
Contineum Therapeutics is a clinical-stage biotech developing small molecule therapies for neuroscience, inflammation, and immunology.
What CONTINEUM THERAPEUTICS INC CLASS A does
Contineum Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapies for the treatment of neuroscience, inflammation, and immunology (NI&I) indications. The company leverages its proprietary platform to identify novel targets and develop pipeline assets designed to address significant unmet medical needs.
Themes: drug discovery, neuroscience drug development, immunology research, small molecule therapeutics
Fundamentals
- Price$8.35 as of 2026-10-21 close
- Market cap$314M as of 2026-07-24 (share count; price 2026-10-21)
- 1-year return-24.5% 2025-10-21 close $11.06 → 2026-10-21 close $8.35
- P/En/a negative earnings
- ROE-23.0% FY2025, SEC XBRL
- ROICn/a No figure: its pre-tax income was zero or negative, so there is no tax rate to apply.
- Debt / equityn/a No figure: its filing tags none of the debt lines we read, which is not evidence of zero debt.
- Beta0.60 as of 2026-09-03
- Last reported earnings2026-07-30 SEC EDGAR Form 8-K (Item 2.02)
How CTNM compares in its sector
- return on equitymiddle range 510 covered Health Care peers, as of 2026-09-03
- free cash flow (absolute dollars, latest fiscal year)middle range 494 covered Health Care peers, as of FY2025
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
Quarterly results
| Quarter | Revenue | Operating income | Net income | Diluted EPS | Operating cash flow | Capex |
|---|---|---|---|---|---|---|
| Q2 FY2026 2026-06-30 | — | -$17M | -$15M | -$0.40 | -$12M† | $6000† |
| Q1 FY2026 2026-03-31 | — | -$17M | -$14M | -$0.39 | -$16M | $312000 |
| Q4 FY2025 2025-12-31 | — | -$17M† | -$15M† | — | -$13M† | $42000† |
| Q3 FY2025 2025-09-30 | — | -$15M | -$13M | — | -$12M† | $98000† |
| Q2 FY2025 2025-06-30 | — | -$18M | -$16M | -$0.62 | -$16M† | $44000† |
| Q1 FY2025 2025-03-31 | — | -$18M | -$16M | -$0.62 | -$14M | $47000 |
| Q4 FY2024 2024-12-31 | — | -$17M† | -$15M† | -$0.57† | -$10M† | $166000† |
| Q3 FY2024 2024-09-30 | $0 | -$13M | -$10M | -$0.40 | -$6M† | $82000† |
† Not filed as a discrete quarter: derived from the company's own year-to-date figures (for example the fourth quarter as the fiscal year minus the first nine months). A derived per-share figure is approximate, because the share count moves within the year.
Balance sheet at 2026-06-30
- Cash and equivalents$15M
- Short-term investments$222M
- Total debtnot shown the filing tags none of the debt lines we read — not evidence of zero debt
From the company's own SEC 10-Q and 10-K filings (XBRL), re-read every week. Figures in US dollars as filed; informational only — not financial advice.
How CONTINEUM THERAPEUTICS INC CLASS A looks technically
CONTINEUM THERAPEUTICS INC CLASS A (CTNM) is trading 38.5% below its 200-day average, the long-term trend line — a long-term downtrend. Its 50-day average crossed above its 200-day average about 273 trading days ago — a "golden cross", a bullish long-term signal. A strong downtrend is in place — ADX, a 0–100 trend-strength gauge, is 42, with sellers in control. Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 33, neither overbought (above 70) nor oversold (below 30). MACD, a trend-momentum gauge, turned bearish about 8 trading days ago (its momentum flipped negative). It made a new 20-day low about 4 trading days ago. It is 53.1% below its highest point of the past year.
Trend
8
| Distance from the 200-day | it is trading 38.5% below its 200-day average, the long-term trend line — a long-term downtrend | -38.5% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $13.58 | $13.58 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $13.57 | $13.57 |
| Swing structure | each recent peak has been lower than the one before it and each dip deeper — the pattern chart-watchers call a downtrend, which describes where price has already been and not where it goes next | lower highs and lower lows |
| Last swing turn | its last significant turn was a swing high 12 calendar days ago — the swings before that are what the structure reading is measured on | 12 sessions |
| Wave structure | its recent swings can be read as a five-part downward sequence — what Elliott-wave chartists call an impulse — now in leg 3 of five; the labelling fails if price closes above 13.855. It is one of several labellings that fit, and it describes the swings already printed, not what comes next. The same swings also read as a three-part correction in leg C. | possible downward five-wave sequence, in wave 3 (one of several readings) |
| Since the 50/200 cross | its 50-day average crossed above its 200-day average about 273 trading days ago — a "golden cross", a bullish long-term signal | 273 sessions |
| Trend strength (14-day ADX) | a strong downtrend is in place — ADX, a 0–100 trend-strength gauge, is 42, with sellers in control | 42.4 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 33, neither overbought (above 70) nor oversold (below 30) | 32.7 |
|---|---|---|
| Position in its 14-day range | it is trading in the lower half of its 14-day range ($6.72 to $13.86) — its "stochastic" reading is 23 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been climbing within that range over the last few sessions. | 22.8 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, turned bearish about 8 trading days ago (its momentum flipped negative) | 8 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $17.79 | $17.79 |
|---|---|---|
| From the 52-week high | it is 53.1% below its 52-week high (its highest price of the past year) | -53.0% |
| Above the 52-week low | it is 24.2% above its 52-week low (its lowest price of the past year) | +24.2% |
| Below the 52-week high | it is 53.1% below its highest point of the past year | 53.0% |
| Since a 20-day breakout | it made a new 20-day low about 4 trading days ago | 4 sessions |
| Since a 55-day breakout | it made a new 55-day low about 4 trading days ago | 4 sessions |
| All-time high | its highest closing price on record is $22.00 (set on 2024-07-01) | $22.00 |
| Given back of the 52-week move | over the past year its closes ranged ($7.08 to $17.57), and it has recovered only a small part of its fall from last year’s high — 12% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $13.56 to $13.90. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 12.1% |
| From the all-time high | it is 62.0% below its all-time high | -62.0% |
| Nearest price level | it is trading 4.9% above a support level at $7.94 — a price it turned at twice since 2025-03-11, most recently on 2025-03-25. Since 2024-10-21 it has 2 such levels below the current price and 12 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | -4.9% |
| All-time low | its lowest closing price on record is $3.35 (set on 2025-05-28) | $3.35 |
| Above the all-time low | it is 149.3% above its all-time low | +149.3% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are unusually wide versus its own recent history (wider than about 99% of the past ~6 months) | 99th percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $1.14 between its high and its low — about 13.7% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $1.14 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $6.14 and $15.64 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $6.14 – $10.89 – $15.64 |
| Typical daily range (% of price) | its price moves about 13.7% in a typical session — among the most volatile in the catalog. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 13.7% |
| Stretch from the 200-day average | it is trading 4.6 daily ranges below its 200-day average price (38.5% below it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 4.6 daily ranges below its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 0.95× |
|---|
Analyst
2
| Change in the average price target | analysts have cut their average price target by 1.3% since the prior reading | -1.3% |
|---|---|---|
| Change in the consensus rating | the analyst consensus rating has softened toward "sell" since the prior reading | 0.25 toward sell |
Candlestick patterns
1
| Since a doji | 5 sessions ago it opened and closed at almost the same price after trading through a wider range — a "doji", the classic picture of buyers and sellers finishing the session level | 5 sessions ago |
|---|
Price gaps
3
| Gap at the open | it opened on 2026-10-21 0.4% above the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and traded back through that level before the close | +0.3% |
|---|---|---|
| Open gap | it gapped 26.0% below the previous close 7 sessions ago and has not traded back through the level it left behind at 13.38 — an "unfilled gap", which describes a price range no trade has since crossed and is not a forecast that it will be crossed | -26.0% |
| Gap filled | a 2.5% gap down opened on 2026-10-14 has been "filled" 5 sessions ago — price traded back through the level the gap left behind, and it closed again during the very session that opened it | 5 sessions ago |
Price streaks
1
| Closing streak | it closed lower in its latest session, after a session that did not close lower — a single down day rather than a run | 1 session down |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock lagged the market by 38.3 percentage points (the stock lost 38.4% while the market lost 0.1%) | -38.3% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock lagged the market by 43.2 percentage points (the stock lost 39.9% while the market gained 3.3%) | -43.2% |
| vs market, 6 months | over the past 6 months this stock lagged the market by 46.3 percentage points (the stock lost 36.5% while the market gained 9.8%) | -46.3% |
| vs market, 12 months | over the past 12 months this stock lagged the market by 39.7 percentage points (the stock lost 24.5% while the market gained 15.2%) | -39.7% |
Signal agreement
2
| Bullish technical signals | 1 of the 9 technical signals we can compute for it is currently in a bullish state: a "golden cross" — its 50-day average is above its 200-day — these describe past price behaviour, not a forecast | 1 of 9 |
|---|---|---|
| Bearish technical signals | 5 of the 9 technical signals we can compute for it are currently in a bearish state: trading below its 200-day average, MACD momentum is negative, a strong downtrend, with sellers in control, lagging the market over 6 months, trading below the Ichimoku cloud — these describe past price behaviour, not a forecast | 5 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 46% below the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-09-15 and projected forward over today's price, the side traders read as an established downtrend, with the band above acting as the level that would have to be cleared. The band itself is thin, spanning 0.0% of the share price, which is taken to mean a barrier that gives way easily. | -45.9% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 34% below the average price paid so far this year, so the typical buyer over that stretch is under water. That average is $12.68 — a volume-weighted average of daily closes over 199 sessions, not a true tick-by-tick VWAP. | -34.1% |
|---|---|---|
| Vs the average paid since it last reported | the price is 30% below the average price paid since it last reported on 2026-07-30 (its 10-Q), so the typical buyer over that stretch is under water. That average is $12.00 — a volume-weighted average of daily closes over 59 sessions, not a true tick-by-tick VWAP. | -30.4% |
Price levels it has turned at before
CTNM last closed at $8.35 on 2026-10-21. Since 2024-10-21 it has turned at 2 prices below its last close and 12 above; the 2 nearest below and the 3 nearest above are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $7.94 | Support | 4.9% below the last close | turned there twice · 2025-03-11 to 2025-03-25 |
| $10.17 | Resistance | 21.8% above the last close | turned there four times · 2025-09-25 to 2025-11-24 |
| $11.32 | Resistance | 35.6% above the last close | turned there twice · 2025-12-19 to 2026-06-23 |
| $5.04 | Support | 39.6% below the last close | turned there twice · 2025-06-10 to 2025-08-01 |
| $11.79 | Resistance | 41.2% above the last close | turned there twice · 2026-03-19 to 2026-04-30 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
Its recent swings can be read as a five-part downward sequence — what Elliott-wave chartists call an impulse — now in leg 3 of five.
This labelling fails — stops being a possible reading at all — if it closes above $13.86.
This is one of several labellings that fit the same swings, so treat it as a reading rather than the reading. It was chosen from 2 labellings that survived the rules, counting shorter readings of the same bars.
On past moves of this shape the leg has usually ended somewhere between $2.62 and $6.91 — that is where it has tended to end if the count holds, not a forecast of where the price goes.
Alternate reading: The same swings also read as a three-part correction in leg C, which fails on a close above $13.86.
This reading has stood for 11 trading days, since 2026-10-07.
Read from daily closes as of 2026-10-21.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading below the 200-day moving average · Trading below the 50-day moving average · Pulled back from the 12-month high · Analyst price target recently CUT · lagging the market · Most volatile (6%+ typical daily range) | Learn: moving average · golden cross · adx · rsi · macd · breakout · fifty two week high low
Based on daily closing prices as of 2026-10-21. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingBuy (1.63 mean, 1=Strong Buy…5=Strong Sell) — 7 analysts
- Mean price target$22.14 range $14.00 – $30.00; median $22.00
Analyst estimates, as of 2026-10-15. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for CTNM
- Consensus EPS estimate-$0.4529 next reporting period, as of 2026-10-15
- Estimate change, 30 days+$0.00143 from -$0.4543, on 2026-09-10, 35-day window
- Readings revised upward22% of 9 comparable readings
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["The company is in the early stages of clinical development and faces substantial risk that its product candidates will fail to demonstrate safety or efficacy.","The company has a history of operating losses and expects to incur significant additional losses as it continues its research and development efforts."]
What changed in the latest 10-Q
AI-assisted comparison of CTNM's 10-Q filed 2026-07-30 against the prior one filed 2026-05-05.
Management's Discussion & Analysis (MD&A)
- Added:
- Newer filing (2026-07-30) states PIPE-791 is in development for 'idiopathic pulmonary fibrosis (IPF) and chronic pain' and references 'other fibrotic diseases'.
- Newer filing (2026-07-30) describes PIPE-791 as having 'broad therapeutic potential (portfolio in a pill)'.
- Newer filing (2026-07-30) states 'The Company initiated patient dosing in PROPEL-IPF, a global Phase 2 clinical trial evaluating PIPE-791 for the treatment of patients with IPF, in the first quarter of 2026.'
- Newer filing (2026-07-30) states 'PROPEL-IPF is a 26-week, randomized, double-blind, placebo-controlled clinical trial evaluating the efficacy, safety, tolerability and pharmacokinetics of once-daily, oral PIPE-791 in approximately 324 IPF patients. The primary efficacy endpoint is the change from baseline through week 26 in absolute forced vital capacity (FVC mL). To date, the Company has activated more than 50 clinical trial sites.'
- Newer filing (2026-07-30) states the Phase 1b chronic pain trial demonstrated 'no clinically-relevant orthostatic events'.
- Newer filing (2026-07-30) states PIPE-307 is 'in development for depression' only.
- Newer filing (2026-07-30) states 'J&J completed enrollment of 107 adult participants for its Phase 2 Moonlight-1 trial of PIPE-307, renamed by J&J to JNJ-89495120, in June 2026.'
- Newer filing (2026-07-30) footnote (1) states only: 'We made a strategic decision to defer further clinical development for our CTX-343 program until funding is obtained to specifically move this program forward.'
- Newer filing (2026-07-30) footnote (2) states: 'J&J has sole discretion whether or not to further develop PIPE-307 for MDD or any other indication.'
- Newer filing (2026-07-30) refers to 'various indications' rather than 'other NI&I indications' for preclinical and discovery-phase experiments.
- Removed:
- Older filing (2026-05-05) described the company as 'pioneering differentiated therapies for the treatment of NI&I indications with significant unmet need.'
- Older filing (2026-05-05) stated PIPE-791 and PIPE-307 'will have broad applicability across multiple NI&I indications.'
- Older filing (2026-05-05) described PIPE-791 as targeting the 'lysophosphatidic acid 1 receptor (LPA1R)'.
- Older filing (2026-05-05) stated the Phase 2 trial of PIPE-791 in IPF 'was initiated in December 2025.'
- Older filing (2026-05-05) described PIPE-307 as 'in development for depression and relapse-remitting multiple sclerosis (RRMS)'.
- Older filing (2026-05-05) stated 'In December 2024, J&J began recruiting an estimated 124 adult participants for the Phase 2 Moonlight-1 trial of PIPE-307' and 'We estimate this trial to be completed in June 2026.'
- Older filing (2026-05-05) reported top-line data from the Phase 2 VISTA trial of PIPE-307 in RRMS: 'The trial demonstrated acceptable safety and tolerability at both doses that were investigated in the trial. The trial did not meet its prespecified primary and secondary efficacy endpoints.'
- Older filing (2026-05-05) stated 'J&J has sole discretion whether or not to further develop PIPE-307 for RRMS, MDD, or any other indication.'
- Older filing (2026-05-05) stated 'We believe PIPE-307 is the most advanced selective M1R antagonist in clinical development.'
- Older filing (2026-05-05) described the small molecule programs as targeting 'NI&I indications' and retained 'worldwide rights to our LPA1R programs'.
- Older filing (2026-05-05) footnote (1) stated: 'We made a strategic decision to defer further clinical development of our PIPE-791 progressive multiple sclerosis (PrMS) program and to defer the initiation of clinical development for our CTX-343 program until funding is obtained to specifically move these programs forward.'
- Older filing (2026-05-05) footnote (2) stated: 'J&J has sole discretion whether or not to further develop PIPE-307 for RRMS and MDD.'
- Older filing (2026-05-05) referred to 'other NI&I indications' for preclinical and discovery-phase experiments.
- Reworded:
- Newer filing (2026-07-30) changes 'lysophosphatidic acid 1 receptor (LPA1R)' to 'lysophosphatidic acid receptor 1 (LPAR1)' throughout.
- Newer filing (2026-07-30) replaces 'differentiated therapies for the treatment of NI&I indications' with 'structurally differentiated small molecule therapies for inflammatory and fibrotic diseases'.
- Newer filing (2026-07-30) replaces 'differentiated LPA1R therapy' with 'differentiated LPAR1 therapy with broad therapeutic potential (portfolio in a pill)'.
- Newer filing (2026-07-30) replaces 'Our second novel drug candidate, PIPE-307' with 'Our partnered novel drug candidate, PIPE-307'.
- Newer filing (2026-07-30) replaces 'We retain worldwide rights to our LPA1R programs' with 'We retain worldwide rights to our LPAR1 programs'.
- Newer filing (2026-07-30) replaces 'targeting other NI&I indications' with 'targeting various indications'.
- Both filings contain an identical truncated sentence at the end of the provided text: 'As we continue to pursue our b' / 'As we contin'.
- Notes:
- Both source texts appear truncated at the end, preventing full comparison of the remainder of the MD&A section.
Risk Factors
- Added:
- Newer filing adds the sentence: 'The below risk factor updates and replaces the risk factor with the same title in Part I, Item 1A, "Risk Factors" of the Company's Annual Report on Form 10-K. Except as set forth below, there have been no material changes from the risk factors set forth in Part I, Item 1A of the Company's Annual Report on Form 10-K.' (filed 2026-07-30)
- Newer filing adds the entire risk factor titled 'We currently rely on third-party CMOs for the production of clinical supplies of PIPE-791...' including discussion of PIPE-791, PIPE-307, reliance on CMOs, WuXi AppTec, APIs, raw materials, cGMP compliance, and the BIOSECURE Act (filed 2026-07-30)
- Removed:
- Older filing contains Part II Items 2 through 6 and signature page content that is not present in the newer Risk Factors section (filed 2026-05-05)
- Notes:
- The older filing provided does not appear to contain a comparable Risk Factors disclosure; instead it contains Part II Items 2-6 and signatures. The comparison may be affected by extraction or section truncation differences between the two filings.
- The newer Risk Factors text ends mid-sentence at 'The Office of Management and Budget ("OMB") of the U.' and may be truncated.
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
0 open-market purchases and 2 open-market sales by insiders in the last 90 days, of which we have read Form 4 filings through 2026-10-17. The 5 days since 2026-10-17 have not been checked yet.
- Last 90 days · read to 2026-10-170 buys · 2 sells ($81171) — 1 selling insider
- Last 180 days · read to 2026-10-170 buys · 13 sells ($1M) — 3 selling insiders
Activity heuristic: net selling (a transparent product heuristic from the counts above, not a prediction or advice)
Most recent open-market transaction: 2026-09-08. Based on Form 4 filings read through 2026-10-17; anything filed since is not yet included.
View full insider trading history → View SEC Form 3/4/5 filingsAsk about CTNM's insider activity →
Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Institutional ownership (13F)
5 institutional 13F filers reported holding CTNM as of 2026-06-30 (quarter-end position, filed within 45 days).
- Distinct 13F filers 5
- Reported shares held 4,390,385
- Reported value $71,958,410
reported quarterly holdings change (2026-03-31 → 2026-06-30): 0 new, 4 increased, 1 decreased, 0 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Ask about CTNM's institutional holders → See what each manager we track holds →
Short interest (FINRA)
CTNM had 3,067,588 shares of reported short interest as of the 2026-09-30 FINRA settlement date (delayed, bi-monthly; not real-time).
Short interest as a percent of shares outstanding is not shown for CTNM because we do not hold a verified share count to divide it by. The reported figures above are unaffected.
- Reported short interest (shares) 3,067,588
- Prior settlement (shares) 2,443,708
- Reported change 25.53%
- Days to cover (reported) 3.62
Reported to FINRA as of the 2026-09-30 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- Eli Lilly (LLY)
- AbbVie (ABBV)
- Bristol Myers Squibb (BMY)
- Sanofi (SNY)
- Novartis (NVS)
- Vertex Pharmaceuticals (VRTX)
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare CTNM vs…
CONTINEUM THERAPEUTICS INC CLASS A is found in…
Frequently asked questions
What does CONTINEUM THERAPEUTICS INC CLASS A (CTNM) do?
Contineum Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapies for the treatment of neuroscience, inflammation, and immunology (NI&I) indications. The company leverages its proprietary platform to identify novel targets and develop pipeline assets designed to address significant unmet medical needs.
What sector is CONTINEUM THERAPEUTICS INC CLASS A (CTNM) in?
CONTINEUM THERAPEUTICS INC CLASS A (CTNM) is classified in the Health Care sector. Its industry is biotechnology. It trades on NASDAQ.
Who are CONTINEUM THERAPEUTICS INC CLASS A's (CTNM) competitors?
Notable peers of CONTINEUM THERAPEUTICS INC CLASS A (CTNM) include Eli Lilly, AbbVie, Bristol Myers Squibb, Sanofi and Novartis. This peer set is informational only — not financial advice.
Is CONTINEUM THERAPEUTICS INC CLASS A (CTNM) overbought or oversold right now?
CONTINEUM THERAPEUTICS INC CLASS A (CTNM) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 33, in the neutral middle (as of 2026-10-21). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on CTNM come from?
Fundamentals come from SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest; prices are market data, as of 2026-09-03; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-21.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.